This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are as essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.

Necessary Always Enabled

Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.

Recent News

amcure to Present Data on the Mode of Action of its Lead Compound AMC303 at the AACR Annual Meeting 2019.

amcure Presents First Clinical Data for Lead Compound AMC303 at ESMO 2018 Congress.

amcure Announces First Patient Dosed with AMC303 in Phase Ib Extension Cohort Based on Positive Safety Results.

amcure Presents Pre-Clinical Anti-tumor and Anti-Metastatic Effects of AMC303 at AACR.

amcure Appoints Biotech Executive Heinz Schwer to its Board.

amcure Presents Phase I/Ib Study Design for Lead Compound AMC303 at ESMO 2017 Congress.

Events

ESMO 2018 – Munich, Germany

BioEurope – Berlin, Germany

ESMO 2017 – Madrid, Spain

ASCO 2017 – Chicago, Illinios, USA

AACR – Washington D.C., USA

BioEurope | Cologne, Germany